3 years ago

Phase 2b trial of a novel extended-release microsphere formulation of triamcinolone acetonide for intra-articular injection in knee osteoarthritis

Stanley B Cohen, Neil Bodick, Joelle Lufkin, Francis Berenbaum, James R Johnson, Philip G Conaghan
Objective FX006 is a novel, microsphere-based, extended-release formulation of triamcinolone acetonide (TA) for intra-articular injection designed to maintain TA joint concentration and provide prolonged analgesic benefits in patients with osteoarthritis (OA) of the knee. The aim of this study was to compare the analgesic benefits of two FX006 doses with saline-placebo injection. Methods In this Phase 2b study, participants with knee OA (Kellgren-Lawrence Grade 2–3) and average daily pain (ADP)-intensity ≥5 to ≤9 (0–10 Numeric Rating Scale) were randomized (1:1:1) and received single IA injections of FX006 32 mg (N=104) or 16 mg (N=102) or saline-placebo (N=100). The primary endpoint was least-squares-mean (LSM) change from baseline to Week 12 in weekly mean ADP-intensity scores for FX006 32 mg versus saline-placebo. Results The primary endpoint was not met (FX006 32 mg versus saline-placebo LSM-change at Week 12: −3.1 versus −2.5; LSM-difference [95% confidence interval] of −0.58 [−1.22, 0.07]; P = 0.08). However, FX006 32 mg improvements were significant versus saline-placebo at Weeks 1–11 and Week 13. FX006 16 mg improvements were significant versus saline-placebo at Weeks 1–9. A dose-response was evident in duration of maximal analgesic effect (32 mg: 13 weeks versus 16 mg: 9 weeks), with FX006 32 mg providing increased therapeutic benefit relative to FX006 16 mg. All treatments were well-tolerated. Conclusion Although the primary endpoint was not met, FX006 demonstrated a prolonged reduction in symptoms with an evident dose response and a safety profile similar to that of saline-placebo. This article is protected by copyright. All rights reserved.

Publisher URL: http://onlinelibrary.wiley.com/resolve/doi

DOI: 10.1002/art.40364

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.